XETRA · M12.DE
M1 Kliniken AG
€19.70+€0.26 (+1.34%)
M1 Kliniken AG’s quoted price sits in the upper half of its reported 52-week range, 9.22% below the high.
Loading market information…
XETRA · SBS.DE · EUR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Stratec SE’s quoted price sits in the upper half of its reported 52-week range, 14.31% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Stratec SE’s forward annual dividend is €0.60 per share, paid annual. The forward yield is 2.64% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Stratec SE’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of €0.15. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Stratec SE’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Established in 1979 and headquartered in Birkenfeld, Germany, Stratec SE (previously known as STRATEC Biomedical AG until its name change in December 2018) specializes in the development and manufacturing of cutting-edge automation and instrumentation systems. The company caters to the in-vitro diagnostics and life sciences sectors, operating across Germany, the European Union, and globally. Its business is divided into three primary segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment focuses on designing and fabricating automated analytical systems, along with necessary spare parts and supplies, for customers in clinical diagnostics and biotechnology. The Diatron segment provides a suite of systems, components, disposables, and assays for lower-volume hematology and clinical chemistry applications. Finally, the Smart Consumables segment is dedicated to engineering and producing intelligent consumables for the diagnostics, life sciences, and medical technology industries.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| €60.40M |
| Q1 2025 | May 19, 2025 | €0.97+155.26% vs estimate | €81.30M-0.12% vs estimate |
|---|
| Q3 2024 | Oct 17, 2024 | €0.05-86.84% vs estimate | €57.20M-6.27% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€19.70+€0.26 (+1.34%)
M1 Kliniken AG’s quoted price sits in the upper half of its reported 52-week range, 9.22% below the high.
€19.10-€0.06 (-0.31%)
Formycon AG’s quoted price sits in the lower half of its reported 52-week range, 29.13% below the high.
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
€10.72+€0.26 (+2.49%)
Medios AG’s quoted price sits in the lower half of its reported 52-week range, 38.53% below the high.
€5.35+€0.10 (+1.9%)
Mediclin AG’s quoted price sits in the upper half of its reported 52-week range, 7.76% below the high.
CA$3.73-CA$0.05 (-1.32%)
High Tide Inc.’s quoted price sits in the upper half of its reported 52-week range, 15.03% below the high.
CHF 9.13+CHF 0.29 (+3.28%)
Newron Pharmaceuticals S.p.A.’s quoted price sits in the lower half of its reported 52-week range, 71.33% below the high.
€525.00+€5.00 (+0.96%)
LIMES Schlosskliniken AG’s quoted price sits in the upper half of its reported 52-week range, 11.76% below the high.
